https://www.nasdaq.com/press-release/assertio-holdings-inc.-announces-the-acquisition-of-otrexupr-methotrexate-a-drug
https://www.nasdaq.com/press-release/sidoti-december-micro-cap-virtual-conference-2021-12-07
https://www.nasdaq.com/press-release/assertio-holdings-inc.-announces-preliminary-court-approval-of-shareholder-derivative
https://www.nasdaq.com/press-release/sidoti-microcap-virtual-conference-2021-11-05
https://www.nasdaq.com/press-release/assertio-reports-third-quarter-2021-financial-results-2021-11-04
https://www.nasdaq.com/press-release/assertio-holdings-inc.-to-report-third-quarter-2021-financial-results-after-the-close
https://www.nasdaq.com/press-release/assertio-holdings-inc.-to-participate-in-upcoming-investor-events-2021-10-04
https://www.nasdaq.com/press-release/assertio-reports-second-quarter-2021-financial-results-2021-08-05
https://www.nasdaq.com/press-release/assertio-holdings-inc.-to-report-second-quarter-2021-financial-results-after-the
https://www.nasdaq.com/press-release/assertio-holdings-inc.-regains-compliance-with-nasdaq-minimum-bid-price-requirement
https://www.nasdaq.com/press-release/assertio-holdings-inc.-announces-1-for-4-reverse-stock-split-2021-05-17
https://www.nasdaq.com/press-release/assertio-holdings-inc.-announces-adjournment-of-annual-meeting-of-shareholders-2021
https://www.nasdaq.com/press-release/assertio-reports-first-quarter-2021-financial-results-2021-05-06
https://www.nasdaq.com/press-release/assertio-holdings-inc.-partners-with-cove-a-leading-migraine-telemedicine-platform-to
https://www.nasdaq.com/press-release/assertio-holdings-inc.-to-report-first-quarter-2021-financial-results-after-the-close
https://www.nasdaq.com/press-release/assertio-reports-fourth-quarter-and-full-year-2020-financial-results-2021-03-11
https://www.nasdaq.com/press-release/assertio-holdings-inc.-to-present-at-virtual-roth-conference-on-monday-march-15-2021
https://www.nasdaq.com/press-release/assertio-holdings-inc.-to-report-fourth-quarter-and-full-year-2020-financial-results
https://www.nasdaq.com/press-release/assertio-holdings-inc.-announces-closing-of-registered-direct-offering-of-%2434.3
https://www.nasdaq.com/press-release/assertio-holdings-inc.-announces-pricing-of-%2434.3-million-registered-direct-offering
https://www.nasdaq.com/press-release/assertio-holdings-inc.-announces-closing-of-registered-direct-offering-of-%2414-million
https://www.nasdaq.com/press-release/assertio-holdings-inc.-announces-pricing-of-%2414-million-registered-direct-offering
https://www.nasdaq.com/press-release/assertio-announces-%245.0-million-insurance-settlement-and-general-corporate-updates
https://www.nasdaq.com/press-release/assertio-announces-transfer-of-listing-from-nasdaq-global-select-market-to-nasdaq
https://www.nasdaq.com/press-release/assertio-announces-restructuring-plan-and-leadership-changes-2020-12-15
https://www.nasdaq.com/press-release/assertio-to-present-at-the-stifel-2020-virtual-healthcare-conference-on-november-17
https://www.nasdaq.com/press-release/assertio-reports-third-quarter-2020-financial-results-2020-11-06
https://www.nasdaq.com/press-release/assertio-to-release-third-quarter-2020-financial-results-and-host-webcast-on-november
https://www.nasdaq.com/press-release/assertio-to-present-at-cantor-virtual-global-healthcare-conference-on-september-16
https://www.nasdaq.com/press-release/assertio-reports-second-quarter-2020-financial-results-2020-08-07
https://www.nasdaq.com/press-release/assertio-to-release-second-quarter-2020-financial-results-and-host-webcast-on-august
https://www.nasdaq.com/press-release/assertio-therapeutics-announces-first-quarter-2020-results-2020-05-11
https://www.nasdaq.com/press-release/assertio-therapeutics-announces-its-virtual-2020-annual-meeting-on-may-19-2020-and
https://www.nasdaq.com/press-release/assertio-therapeutics-announces-completion-and-final-results-of-the-offer-to-purchase
https://www.nasdaq.com/press-release/assertio-therapeutics-agrees-to-merge-with-zyla-life-sciences-to-create-synergistic
https://www.nasdaq.com/press-release/assertio-therapeutics-announces-offer-to-purchase-all-of-its-issued-and-outstanding-2
https://www.nasdaq.com/press-release/assertio-therapeutics-announces-fourth-quarter-and-full-year-2019-financial-results
https://www.nasdaq.com/press-release/assertio-therapeutics-to-report-fourth-quarter-and-full-year-2019-financial-results
https://www.nasdaq.com/press-release/assertio-therapeutics-announces-repurchase-of-approximately-%24188.0-million-of-its
https://www.nasdaq.com/press-release/assertio-therapeutics-announces-closing-of-sale-of-nucyntar-franchise-to-collegium
https://www.nasdaq.com/press-release/assertio-therapeutics-announces-sale-of-nucyntar-franchise-to-collegium
https://www.nasdaq.com/press-release/assertio-therapeutics-announces-closing-of-graliser-sale-to-alvogen-and-expects-full
https://www.nasdaq.com/press-release/assertio-therapeutics-announces-sale-of-graliser-for-total-transaction-value-of-%24127
https://www.nasdaq.com/press-release/assertio-therapeutics-to-present-at-the-31st-annual-piper-jaffray-healthcare
https://www.nasdaq.com/press-release/assertio-therapeutics-to-present-at-the-2019-stifel-healthcare-conference-2019-11-13
https://www.nasdaq.com/press-release/assertio-therapeutics-announces-third-quarter-2019-results-2019-11-06
https://www.nasdaq.com/press-release/ceridian-hcm-holding-bjs-wholesale-club-holdings-set-to-join-sp-midcap-400
https://www.nasdaq.com/press-release/assertio-therapeutics-to-report-third-quarter-2019-financial-results-after-the-close
